European equities traded in the US as American depositary receipts were down 0.59% to 1,896.05 on the S&P Europe Select ADR Index late Friday morning. For the week, the index is little changed so far.
From continental Europe, the gainers were led by pharmaceutical firm Sanofi (SNY) and biopharmaceutical firm Grifols (GRFS), which rose 3.5% and 2.5% respectively. They were followed by petroleum refiner Equinor (EQNR) and pharmaceutical firm Novo Nordisk (NVO), which were up 2.2% and 1.9% respectively.
The decliners from continental Europe were led by telecommunications firm Nokia (NOK) and biopharmaceutical firm DBV Technologies (DBVT), which fell 6.9% and 6% respectively. They were followed by biopharmaceutical firm Cellectis (CLLS) and internet browser company Opera (OPRA), which were down 4.8% and 4.1% respectively.
The gainers from the UK were led by Akari Therapeutics (AKTX) and pharmaceutical company AstraZeneca (AZN), which rose 6.9% and 6.4% respectively. They were followed by alcoholic beverage company Diageo (DEO) and software firm Endava (DAVA), which increased 2.5% and 2.3% respectively.
The decliners from the UK and Ireland were led by Biodexa Pharmaceuticals (BDRX) and Lloyds Banking Group (LYG), which lost 4.4% and 4.3% respectively. They were followed by biopharmaceutical company Amarin (AMRN) and Trinity Biotech (TRIB), which dropped 4.1% and 3.5% respectively.
Source: finance.yahoo.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.
